The Early and Late Clinical Outcomes of Diabetic Patients Complicated with Acute Myocardial Infarction Treated by Primary Percutaneous Transluminal Coronary Angioplasty

赵明中,胡大一,李田昌,杨明,贾三庆,任文林,李瑞杰,许玉韵
DOI: https://doi.org/10.3760/j:issn:0253-3758.2001.03.006
2001-01-01
Journal of Clinical Cardiology
Abstract:Objective To evaluate the early and late clinical outcomes ofdiabetic patients complicated with acute myocardial infarction (AMI) treated by primary percutaneous transluminal coronary angioplasty(P-PTCA). Methods Three hundred and thirty nine patients with AMI consecutively treated by PTCA were divided into diabetes group(63 cases )and non-diabetes group (276 cases).The baseline clinical characteristics, coronary angiogram and major cardiovascular events(MACE) were analysed. Results No significant differences were observed in coronary artery lesions between the two groups. During early follow-up period (within 1 month), the left ventricular ejection fraction(LVEF) was lower(0.54±0.10 vs 0.60±0.13, P<0.05), and the incidence of non-fatal heart failure was higher (16.7% vs 7.1%, P<0.05) in diabetes group than in non-diabetes group, but cardiac death rate was similar in the two groups(P>0.05). At late follow-up period (mean 20.6±8.7 months), the incidence of non-fatal heart failure and rate of target vessel revascularization increased (P<0.05, P<0.01, respectively), the incidence of MACE also increased (63.0% vs 32.7%,P<0.01) and survival rate freedom from MACE decreased (37.0% vs 67.3%, P<0.01) in diabetes group, compared with those in non-diabetes group, but total cardiac mortality rates were similar in the two groups (7.4% vs 3.9%,P>0.05). Multivariate analysis indicated that diabetes and the value of LVEF were associated with incidence of MACE and each was respectively independent risk factor affecting survival rate freedom from MACE, diabetes was the stronger predictor for the decreased survival rate from MACE (RR 4.15, 95% CI:1.29-15.62). Conclusions Survival rate freedom from MACE was lower in AMI patients with than without diabetes treated by P-PTCA, but overall cardiac mortality rates were similar in the two groups, which suggest that P-PTCA in diabetes maybe more likely to reduce the clinical mortality rate as compared with previous reports about thrombolytic therapy.
What problem does this paper attempt to address?